Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

NCT05595109 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Peripheral Neuropathy
Cardiac Toxicities
Hepatic Toxicity
Cognitive Impairment

Interventions

DRUG: Silymarin
DRUG: Placebo

Sponsor

Tanta University